Mesoblast (MESO) Current Deferred Revenue (2015 - 2020)
Mesoblast (MESO) posted quarterly Current Deferred Revenue of $10.0 million for Q2 2020, little changed year-on-year from $10.0 million in Q3 2019, and little changed on a QoQ basis from $10.0 million in Q1 2020.
Mesoblast (MESO) Current Deferred Revenue (2015 - 2020) Analysis & Trends
Mesoblast (MESO) has reported Current Deferred Revenue for 3 consecutive years, with $10.0 million the latest figure, recorded in Q2 2020.
- Quarterly Current Deferred Revenue changed 0.0% year-over-year to $10.0 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $10.0 million (changed 0.0% YoY) and the FY2020 annual result came in at $10.0 million, changed 0.0% from the prior year.
- Current Deferred Revenue was little changed at $10.0 million in Q2 2020 per MESO's latest filing, from $10.0 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for MESO reached as high as $10.0 million in Q1 2019 and fell as low as $10.0 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 10.00 Mn |
| Mar 31, 2020 | 10.00 Mn |
| Dec 31, 2019 | 10.00 Mn |
| Sep 30, 2019 | 10.00 Mn |
| Jun 30, 2019 | 10.00 Mn |
| Mar 31, 2019 | 10.00 Mn |
| Dec 31, 2015 | 15.00 Mn |
| Jun 30, 2015 | 22.51 Mn |